Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BB

Ratings ESG MSCI

Ratings DaShenLin Pharmaceutical Group Co., Ltd.: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.
  • The company's MSCI ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Highlights: DaShenLin Pharmaceutical Group Co., Ltd.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • With regards to fundamentals, the enterprise value to sales ratio is at 0.49 for the current period. Therefore, the company is undervalued.
  • The company has a low valuation given the cash flows generated by its activity.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses: DaShenLin Pharmaceutical Group Co., Ltd.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • The company's earnings releases usually do not meet expectations.

Rating Financials

DaShenLin Pharmaceutical Group Co., Ltd. SectorChina

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

DaShenLin Pharmaceutical Group Co., Ltd. SectorChina

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

DaShenLin Pharmaceutical Group Co., Ltd. SectorChina

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

DaShenLin Pharmaceutical Group Co., Ltd. SectorChina

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

DaShenLin Pharmaceutical Group Co., Ltd. SectorChina

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
2.68B
BB
13.53B
AA
6.76B
AA
5.62B
AAA
3.49B
AAA
3.27B
AAA
3.3B
BBB
2.48B -
BBB
- -
2.46B - - - - -
1.71B
AA
Average 4.53B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. 603233 Stock
  4. Ratings DaShenLin Pharmaceutical Group Co., Ltd.
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!